USA flag logo/image

An Official Website of the United States Government

Hypoxia-Perfusion Bioreactor for Stem Cell Applications

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70904
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
HL072655
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Resodyn Corporation
130 North Main Street Suite 600 Butte, MT 59701-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Hypoxia-Perfusion Bioreactor for Stem Cell Applications
Agency: HHS
Contract: 1R43HL072655-01A1
Award Amount: $155,134.00
 

Abstract:

DESCRIPTION (provided by applicant): Cord blood (CB) cells are a desirable source of stem cells for transplantation because their collection poses no donor impact and they would facilitate the creation of an ethnically diverse pool of donor cells. However, the small quantity of stem cells and the extended cytopenias associated with the use of CB cells for transplantation limit broad application to adult patients. Ex vivo protocols that enable expansion of repopulating stem cells have been developed, but require many weeks of culture, and the use of multiple manipulations and vessels that increase the risk of contamination and limit reproducibility. In order to utilize recent discoveries that low oxygen levels are favorable to stem cell expansion, Resodyn Corporation has developed the hypoxia-perfusion bioreactor (HPB), which is designed to provide controlled delivery of both oxygen and fresh medium to stem cell cultures. It is the aim of this proposal to demonstrate use of the HPB as a simple, inexpensive stem cell enrichment device, and as a stem cell expansion device that can increase the rate and quality of stem cell expansion using current state-of-the-art expansion protocols. In Phase I, feasibility will be demonstrated and the optimal oxygen levels established. In Phase II, cytokine/oxygen interactions will be explored, and a scale-up of protocols and hardware to a clinically-ready system will be accomplished. Phase III will consist of clinical trials to test the efficacy of expanded stem cells. The HPB system has significant long-term commercial potential both in the laboratory as a tool to facilitate development of stem cells protocols, and in the clinic as a component of both CB transplantation and other pre-emerging stem cell protocols of the neural, hematopoietic, and mesenchymal lineages.

Principal Investigator:

Todd A. Mcadams
4067232222
TMCADAMS@RESODYN.COM

Business Contact:

Lawerence Farrar
4067232222
Small Business Information at Submission:

RESODYN CORPORATION
1901 SOUTH FRANKLIN STREET BUTTE, MT 59701

EIN/Tax ID: 810528815
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No